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adalimumab, each administered with methotrexate, in treating
patients with rheumatoid arthritis (RA) stratiﬁed according to baseline
anticitrullinated protein antibody (ACPA) levels (marker of poor prog-
nosis in RA). Methods: A payer-perspective cost-effectiveness model
simulated disease progression in patients with RA who had previously
failed conventional disease-modifying antirheumatic drugs and were
starting biologic therapy. Patients commenced treatment with abata-
cept or adalimumab plus methotrexate and were evaluated after
6 months. Therapy continuation was based on the European League
Against Rheumatism treatment response; disease progression was
based on the Health Assessment Questionnaire Disability Index score.
These score changes were used to estimate health state utilities and
direct medical costs. Quality-adjusted life-years (QALYs) and incre-
mental cost per QALY gained were calculated by baseline ACPA groups
(Q1, 28–234 AU/ml; Q2, 235–609 AU/ml; Q3, 613–1045 AU/ml; and Q4,
1060–4894 AU/ml). Scenario analysis and one-way and probabilistic
sensitivity analyses were used to evaluate robustness of modelee front matter Copyright & 2018, International S
r Inc. This is an open access article under the CC
ons.org/licenses/by-nc-nd/4.0/).
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ndence to: Evo Alemao, Bristol-Myers Squibb Comassumptions. Results: Abatacept resulted in QALY gain versus
adalimumab in ACPA Q1, Q3, and Q4; between-treatment difference
(difference: Q1, 0.115 Q2, 0.009 Q3, 0.045; and Q4, 0.279). Total
lifetime discounted cost was higher for abatacept versus adalimumab
in most quartiles (Q2, £77,612 vs. £77,546; Q3, £74,441 vs. £73,263; and
Q4, £78,428 vs. £76,696) because of longer time on treatment. Incre-
mental cost per QALY for abatacept (vs. adalimumab) was the lowest
in the high ACPA titer group (Q4, £6200/QALY), followed by the next
lowest titer group (Q3, £26,272/QALY). Conclusions: Abatacept is a cost
effective alternative to adalimumab in patients with RA with high
ACPA levels.
Keywords: abatacept, ACPA, adalimumab, cost effectiveness, economic
model, ICER, QALY, rheumatoid arthritis, treatment costs.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Rheumatoid arthritis (RA) imposes substantial economic burden
on patients, their carers, and the health care system. In 2009,
the economic burden of RA was estimated to be up to £4.75 billion
per year in the United Kingdom [1], with other sources estimating
the overall cost to the UK economy of productivity losses at
almost £8 billion per year [2]. About 30% of patients give up
work within 1 year of diagnosis, whereas 60% do so within
6 years [2].
RA is characterized by progressive disability, systemic com-
plications, and early mortality [3]. Autoantibody production,
including rheumatoid factor (RF) and anticitrullinated protein
antibody (ACPA), is believed to play a role in RA disease patho-
genesis, and both RF and ACPA assays may be used to detect RA
[4]. Although the sensitivities of ACPA and RF appear to be
similar, ACPA has demonstrated a higher speciﬁcity than RF indetecting early RA [4], resulting in the incorporation of ACPA
testing into RA diagnostic criteria in 2010 [5].
In ACPA-positive patients, ACPA is associated with the human
leukocyte antigen - antigen D related, which is associated with
severe RA through the involvement of CD4þ T cells [3,6]. Thus,
patients with RA who are ACPA-positive have a less favorable
prognosis and develop a more aggressive disease than those who
are ACPA-negative [7,8], suggesting that this distinction may be of
clinical value [3]. ACPA is relatively stable over time for an individual
patient [9] and, as a biomarker, has been shown to improve the
identiﬁcation of those at risk of developing clinical RA [10,11]. In
addition, it appears that ACPA positivity may be important in
assessing the mortality risk in patients presenting with early RA [12].
Although clinical practice data demonstrate that the presence
of ACPA in people with RA is a strong predictor of structural
damage (joint erosions) and radiographic progression, its predic-
tive value for treatment outcomes is not well understood [4,13].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Enter treatment cycle
Start on etanercept + MTX
Generate patient 
(as defined by ACPA level)
Start on abatacept
(in combination with MTX)
Response to initial treatment 
is evaluated at six months
Start on adalimumab
(in combination with MTX)
Continue on treatment 
(achieving mean HAQ-DI
score reduction)
Discontinue treatment
(due to lack of efficacy and/or AEs)
Yes No
Fig. 1 – Overview of the patient-level simulation model.
ACPA, anticitrullinated protein antibodies; HAQ-DI, Health
Assessment Questionnaire Disability Index; MTX,
methotrexate.
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can vary by ACPA status, and certain biologic disease-modifying
antirheumatic drugs (DMARDs) such as abatacept (Orencias,
Bristol-Myers Squibb, New York, NY, USA) have demonstrated a
better clinical response in ACPA-positive patients compared with
ACPA-negative patients [14].
In the phase IIIB, multinational, prospective, randomized Aba-
tacept versus adaliMumab comParison in bioLogic-naivE (AMPLE)
study of subjects with RA with background methotrexate (MTX),
abatacept was compared directly with adalimumab (Humiras,
AbbVie Inc, North Chicago, IL, USA) in biologic-naive patients with
RA who had inadequate response to MTX [15,16]. In subgroup
analysis by baseline ACPA levels, each treatment was more
effective in ACPA-positive patients than in ACPA-negative patients,
according to various measures. Greater improvements were
observed for patients who received abatacept compared with those
who received adalimumab in the highest ACPA quartiles with
regard to the Disease Activity Score 28 (DAS28) and the Health
Assessment Questionnaire Disability Index (HAQ-DI) score [17].
Notably, the mean improvements in DAS28 and HAQ-DI scores
with abatacept were signiﬁcantly greater for the highest ACPA
concentration quartile than for the lower three quartiles com-
bined, whereas for adalimumab the improvements were similar
across all quartiles for both measures [17]. The effects observed
for patients with higher ACPA titers may be driven in part by
abatacept’s mechanism of action [18]. Abatacept is a selective
modulator of T-cell activation [6]. Abatacept is thought to block
CD28 costimulatory signals required for T-cell activation, thereby
limiting the activation of T cells [19].
Given the observed clinical beneﬁts of abatacept in ACPA-
positive patients, the objective of this analysis was to assess the
beneﬁts and costs of abatacept compared with those of adalimu-
mab, each administered with MTX, in treating patients with RA who
had inadequate response to MTX and stratiﬁed by their baseline
ACPA levels. The choice of adalimumab as a comparator was driven
by data availability, and the AMPLE study was the only published
study to provide a direct comparison with another agent and
presented data by patient ACPA level. Anti–tumor necrosis factors
(TNFs), and in particular adalimumab, are currently the standard of
care in patients who fail MTX; thus, the choice of the comparator is
appropriate from a payer perspective. Given the mechanism of
action of the anti-TNFs, one could assume that the results of this
analysis could be similar to nonadalimumab anti-TNFs.Methods
Overall Model Structure
A cost-effectiveness simulation model was developed on the basis
of an individual patient simulation (IPS) approach. The model
concept is similar to that of the “Birmingham rheumatoid arthritis
model” [20] with certain elements incorporated from the “Shefﬁeld
rheumatoid arthritis health economic model” [21], and it was
programmed in Microsoft Excel. The model (Fig. 1) adopted a
payer perspective and tracked a large number of individual
patients with different baseline characteristics (age, sex, and
HAQ-DI score) over a lifetime, with the follow-up time being
divided into 6-month cycles. Model simulation began after a
patient had failed conventional DMARDs and was eligible for a
biologic DMARD and assumed that each patient received a given
treatment until switching to an alternative treatment. All eligible
patients were prescribed a biologic DMARD in the model. Patients
were generated by sampling from baseline distributions of sex,
age, and HAQ-DI score on the basis of the AMPLE study population.Each generated patient commenced treatment with either abata-
cept or adalimumab in combination with MTX and was evaluated
on that treatment after a ﬁxed time period (i.e., 6 months), after
which the patient either remained on treatment, if the therapy
was effective and there were no adverse effects, or switched to
another biologic DMARD, that is, anti-TNF drug etanercept.
Patients failing on etanercept were switched to palliative care.
Treatment responses for adalimumab and abatacept were
based on the European League Against Rheumatism (EULAR)
criteria at 6 months as measured in the AMPLE study. The EULAR
response criteria classify patients as good responders, moderate
responders, or nonresponders, on the basis of the DAS28-C-
reactive protein (CRP) value at baseline and the change in
DAS28-CRP from baseline to 6 months, using the method of
Fransen and van Riel [22]. Patients who achieved EULAR good or
moderate response were retained on therapy. Apart from lack of
response, switching could also be due to a patient experiencing
adverse effects. For patients who continued on therapy, the length
of time on each treatment was estimated from data presented in a
health technology assessment of RA treatments [23]. Similar to
current modeling approaches in RA, we do not discriminate
between primary treatment failure and secondary treatment.
The ﬁrst treatment switch was treated as a single event, that is,
a composite of lack of efﬁcacy and/or adverse events [24].
Change in the HAQ-DI score (a measure of physical function-
ing) over a lifetime was used to simulate disease progression for
each patient (including mortality). The HAQ-DI score ranged from
0 (best) to 3 (worst) in multiples of 0.125 [25]. If a patient responded
to therapy, then the therapy was assigned with an initial drop in
the HAQ-DI score (i.e., improvement). This HAQ-DI score change
was subtracted from the baseline HAQ-DI score to simulate the
Fig. 2 – Correlation of the HAQ-DI score to EQ-5D utility [23].
EQ-5D, EuroQol ﬁve-dimensional questionnaire; HAQ-DI,
Health Assessment Questionnaire Disability Index.
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 1 9 3 – 2 0 2 195impact of treatment on disease progression. Any improvement in
the HAQ-DI score was lost on quitting the treatment over the
6-month cycle. At the point of treatment failure, the patient
experienced a further increase in the HAQ-DI score (rebound
effect) before commencing the next predeﬁned treatment within
the sequence, at which point the process started again. The
baseline HAQ-DI score and the treatment-speciﬁc HAQ-DI score
change were derived from the AMPLE study. The HAQ-DI score
change was used to estimate health state utility (quality of life)
and direct medical costs (disease-related hospitalization and joint
replacement costs); change in the HAQ-DI score was therefore the
prime driver of both beneﬁts and costs in the model. It was
assumed that a patient’s HAQ-DI score remained constant over
time while receiving treatment with biologic DMARDs, which was
tested in a sensitivity analysis. Patients experienced disease
progression after their initial response to therapy if they discon-
tinued biologic DMARD andmoved to palliative care, in which case
the HAQ-DI score increased at the rate of 0.06/y [23]. HAQ-DI
progression was separated into initial response (i.e., the ﬁrst
6 months) and subsequent response on the basis of treatment
and long-term disease progression.
Death was able to occur at any time within the model (at
6-month intervals) and was RA- and HAQ-DI–dependent. The
probability of mortality was a function of age, sex, and having RA,
using age and sex-speciﬁc mortality rates for the general pop-
ulation and estimates of increased mortality risk by the HAQ-DI
score. Mortality rates were related to the HAQ-DI score over a
given period [26]. A relative risk of 1.33 per unit HAQ-DI was
applied to the general population mortality probabilities [26].Table 1 – Key baseline characteristics of patients modele
Characteristic Quartile by ACPA (a
Q1: 28–234 Q2: 235–609
ABA
(n ¼ 42)
ADA
(n ¼ 55)
ABA
(n ¼ 51)
ADA
(n ¼ 4
Age (y) 52.0 (24.0, 80.0) 58.0 (21.0, 83.0) 50.0 (22.0, 70.0) 50.0 (19.0
Female (%) 84.8 85.2 88.1 83.6
HAQ-DI score 1.3 (0.0, 2.9) 1.4 (0.0, 2.6) 1.4 (0.0, 2.5) 1.3 (0.0,
CRP (mg/dl) 0.8 (0.1, 8.4) 0.6 (0.0, 4.8) 0.9 (0.0, 9.4) 1.3 (0.1,
DAS28-CRP 5.0 (3.1, 7.6) 5.5 (3.1, 7.3) 5.6 (3.5, 7.6) 6.0 (2.8,
Note. Data are expressed as median (minimum, maximum), unless othe
ABA, abatacept; ACPA, anticitrullinated protein antibodies; ADA, adalim
DAS28, Disease Activity Score 28; HAQ-DI, Health Assessment QuestionnQuality-adjusted life-years (QALYs) were calculated on the
basis of the National Institute for Health and Care Excellence
(NICE) reference case [27]. An inverse relationship between the
HAQ-DI score (disease progression) and quality of life was applied
using the EuroQol ﬁve-dimensional questionnaire (EQ-5D) utility
score based on UK tariffs [23]. The regression equation used in the
model to link the HAQ-DI score to EQ-5D scores was a quadratic
equation, of the form EQ-5D utility ¼ 0.804  0.203  HAQ-DI 
0.045  HAQ-DI2 (see Fig. 2) [23]. This equation estimates utilities
less than 0 for the highest values of the HAQ-DI score. Other linear
mapping equations were tested in a sensitivity analysis. We chose
the nonlinear mapping algorithm for the base case because it
provided a better overall model ﬁt compared with a linear
regression model. It was assumed that events (transitions)
occurred about halfway through a cycle and hence a half-cycle
correction was applied by taking the average of the HAQ-DI score
at the beginning and the end of a cycle. Parameter uncertainty
from the mapping algorithm regression equations was taken into
account in the probabilistic sensitivity analysis (PSA).
Model Inputs
Patient Baseline Characteristics
The initial run of the model simulated 15,000 patients with
baseline characteristics taken from the AMPLE study [15,16]. Of
the 646 patients randomized and treated in the AMPLE study,
86.2% (274 of 318) of the abatacept-treated patients and 82% (269
of 328) of the adalimumab-treated patients completed the study.
The overall AMPLE study population is described elsewhere
[15,16]. Patients had baseline ACPA levels in the range of 28 to
4894 AU/ml. In line with the AMPLE study [15,16], patients were
divided into four ACPA groups based on quartiles: Q1 (28–234 AU/ml),
Q2 (235–609 AU/ml), Q3 (613–1045 AU/ml), and Q4 (1060–
4894 AU/ml). The use of ACPA level quartiles rather than ACPA
level as a continuous measure enabled the analysis of subgroups
on the basis of ACPA level while overcoming the limitation of
skewed patient distribution across the ACPA level range. The
baseline patient characteristics of patients in the AMPLE study
according to baseline ACPA groups are presented in Table 1. The
model was run for each ACPA group separately, with efﬁcacy data
(Tables 2 and 3) for the individual quartile groups being derived
from the AMPLE study in each case.Disease Progression and Treatment Sequence
Clinical inputs applied to determine treatment switching and
simulate disease progression comprised EULAR responses ford in the economic model.
nti-CCP2 concentration, AU/ml)
Q3: 613–1045 Q4: 1060–4894
6)
ABA
(n ¼ 46)
ADA
(n ¼ 51)
ABA
(n ¼ 46)
ADA
(n ¼ 51)
, 78.0) 52.0 (21.0, 78.0) 49.0 (22.0, 73.0) 47.5 (25.0, 73.0) 52.0 (26.0, 78.0)
80.4 87.0 82.6 80.4
2.5) 1.7 (0.0, 2.8) 1.6 (0.0, 2.9) 1.4 (0.0, 2.8) 1.6 (0.0, 3.0)
5.8) 0.9 (0.1, 11.3) 1.0 (0.0, 9.0) 0.9 (0.0, 13.9) 0.7 (0.0, 11.8)
7.4) 5.5 (2.8, 8.1) 5.7 (3.7, 7.9) 6.0 (2.7, 7.8) 5.3 (1.7, 7.8)
rwise stated.
umab; CCP2, cyclic citrullinated peptide-2; CRP, C-reactive protein;
aire Disability Index; Q, quartile.
Table 2 – EULAR response probabilities at 6 mo.
Treatment EULAR response at 6 mo (% probability)
Q1 Q2 Q3 Q4
Good Moderate Good Moderate Good Moderate Good Moderate
ABT þ MTX 55.00 22.50 47.92 39.58 40.00 46.67 62.22 33.33
ADA þ MTX 56.00 34.00 52.27 36.36 51.02 30.61 52.08 35.42
ETN þ MTX 49.67 31.74 46.36 33.95 45.25 28.58 46.19 33.06
ABT, abatacept; ADA, adalimumab; ETN, etanercept; EULAR, European League Against Rheumatism; MTX, methotrexate; Q, quartile.
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 1 9 3 – 2 0 2196abatacept and adalimumab at 6 months, on the basis of the
AMPLE study. Patients in the AMPLE study were categorized by
the type of response they achieved at 6 months. No data were
available for etanercept by quartile; its EULAR response by
quartile was derived by estimating the relative rate of response
between each quartile and the overall population for adalimu-
mab in the AMPLE arm and applying these relative rates to the
EULAR response rate for etanercept in an overall population
obtained from a previous mixed treatment comparison [28]
(Table 2). Patients who did not achieve a good or moderate EULAR
response 6 months after switching to etanercept were switched
to palliative care for the remaining duration of the time horizon.Table 4 – Drug treatment costs, treatment monitoringTreatment Duration
Patients who attained a good or moderate response continued on
therapy, with the length of treatment based on a time on treat-
ment survival curve derived from the British Society for Rheu-
matology Biologics Registry data using a Weibull model [23].
Following the approach used previously, the time on treatment
was sampled from this distribution [23]. A curve was generated
for each treatment and a random sample estimate was drawn
from this distribution to determine a time on each treatment for
each simulated patient (mean 4.06 years for abatacept plus MTX
and for adalimumab plus MTX) [23]. In the base case, mean time
on treatment was assumed to be the same for abatacept and
adalimumab in patients with an initial moderate or good
response. In a sensitivity analysis, the mean time on treatment
was allowed to differ between abatacept and adalimumab. A
lifetime time horizon was applied in the base case, aligning with
NICE guidance [27]. Further time horizons were analyzed in
sensitivity analyses. Age-speciﬁc yearly mortality probabilitiesTable 3 – Estimated mean HAQ-DI score change from
baseline for each therapy by quartile [15].
Treatment HAQ-DI score change from baseline (SE)
at 6 mo
Q1 Q2 Q3 Q4
ABT þ MTX 0.58 (0.09) 0.62 (0.08) 0.67 (0.09) 0.95 (0.09)
ADA þ MTX 0.64 (0.08) 0.59 (0.09) 0.63 (0.09) 0.75 (0.09)
ETN þ MTX 0.59 0.54 0.58 0.69
ABT, abatacept; ADA, adalimumab; ETN, etanercept; HAQ-DI,
Health Assessment Questionnaire Disability Index; MTX, metho-
trexate; Q, quartile; SE, standard error.were sourced for the UK population and converted to 6-monthly
rates by applying the methodology of Briggs et al. [29].Treatment Costs and Outcomes
Costs comprised drug costs and monitoring costs and were
calculated in 2015 pound sterling. The model included an annual
drug cost for each treatment, including any initial loading cost
reﬂecting higher dosage and additional monitoring early in
treatment. Drug costs were applied within the model on the
basis of the recommended dosage over each of the model’s
6-month cycles. Drug cost data inputs for the United Kingdom
and annual administration and drug monitoring costs are
presented in Table 4. Unit costs for adalimumab and etanercept
were drawn from the British National Formulary [30]. Given
that a patient access scheme for abatacept is in place in
the United Kingdom, the cost of abatacept was estimated to be
the average cost of a number of biologic DMARDs approved in
the United Kingdom (£9244), to fairly reﬂect actual treatment
costs for abatacept in the country. Additional sensitivity analy-
ses were conducted on the abatacept cost using average cost
across ﬁve major markets as well as using the British National
Formulary list price. To reﬂect clinical practice, no additional
loading dose cost was assumed in the ﬁrst year; this assumption
was also tested in a sensitivity analysis. Monitoring resource use
and costs (biochemical proﬁle, chest x-ray, full blood cell count,
and erythrocyte sedimentation rate) for MTX were calculated to
be £137.13 for the ﬁrst 6 months and £59.63 after 6 months. Itcosts, and acquisition costs.
Treatment Drug cost (steady-state annual cost) (£)
ABT 9244
ADA 9156
ETN 9295
MTX 31.20
Treatment Monitoring cost
(in ﬁrst 6 mo only)
(£)
Monitoring cost
(subsequent 6-mo
cycles) (£)
ABT þ MTX 904.53 164.88
ADA þ MTX 904.53 164.88
ETN þ MTX 904.53 164.88
ABT, abatacept; ADA, adalimumab; ETN, etanercept; MTX,
methotrexate.
Table 5 – Annual cost of hospitalization by the HAQ-DI
score.
HAQ-DI score range Annual cost (£)
0 o 0.5 173.69
0.5 o 1.0 106.39
1 o 1.5 378.36
1.5 o 2.0 543.33
2.0 o 2.5 1293.02
2.5 o 3.0 2788.83
HAQ-DI, Health Assessment Questionnaire Disability Index.
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included within the monitoring for MTX or administration costs.
Costs for hospitalization and joint replacement were assumed to
increase as the HAQ-DI score increased and were derived from a
previous study [28] and inﬂated to 2015 costs using the National
Health Service pay and prices index [31]. The values assumed in
the base case are presented in Table 5.
The cost of ACPA testing was not included in the model
because it is routinely conducted in clinical practice [32] and
EULAR guidelines [33] recommend testing for seropositivity
irrespective of the treatment selected. In addition, the exclusion
of ACPA testing cost is not expected to change the study ﬁndings
because, if included, it would have incurred the same cost for
both treatment arms.
Outcomes included discounted disaggregated costs, QALY,
and incremental cost per QALY gained (incremental cost-
effectiveness ratio [ICER]) as well as undiscounted life-years.
Costs and outcomes were discounted at 3.5% annually, as
speciﬁed for NICE reference case [27].Sensitivity and Scenario Analyses
Univariate sensitivity analysis was used to determine the key
drivers in the model; these were then applied to ACPA Q4,Table 6 – Parameters considered in PSA (applied to
quartile 4).
Parameter Distribution Mean Standard
error
ABT and ADA
EULAR response
rates
Beta See
Table 2
Assumed
10% of
mean
Utility mapping
algorithm
parameters
a Normal 0.804 0.05
b1 Normal 0.203 0.08
b2 Normal 0.045 0.03
Mortality per unit
HAQ-DI score
Lognormal 1.33 0.13
ABT and ADA
HAQ-DI reductions
Normal See
Table 3
See
Table 3
Annual cost of
hospitalization by
HAQ-DI score
Gamma See
Table 5
Assumed
10% of
mean
ABT, abatacept; ADA, adalimumab; EULAR, European League
Against Rheumatism; HAQ-DI, Health Assessment Questionnaire
Disability Index; PSA, probabilistic sensitivity analysis.because this had shown the lowest ICER for abatacept versus
adalimumab. Each variable was varied individually to assess the
proportional effect on model results. The variables investigated
were abatacept drug cost, abatacept EULAR response rate (good),
initial 6-month HAQ-DI score change, and annual HAQ-DI score
change while on long-term treatment. Additional scenario anal-
yses were conducted on the basis of different time horizons, the
incorporation of an additional (ﬁrst year) loading dose cost for
abatacept, the application of alternative utility mapping equa-
tions, and the incorporation of a longer term of treatment
(6.17 years) for abatacept.
A PSA was performed for ACPA Q4 for 1000 sets of 1000
patients to assess the impact of parameter uncertainty around
major model inputs. Key model parameters were sampled from
parametric distributions to generate 1000 estimates of the costs
and effects in each arm. EULAR response rates followed beta
distributions, nondrug costs, and HAQ-DI score changes; param-
eters of the utility equation followed normal distributions; mor-
tality relative risk followed a lognormal distribution; and
hospitalization costs followed gamma distributions (Table 6).Results
Primary Economic Analyses
The primary analysis considered the cost effectiveness of abata-
cept plus MTX as a ﬁrst-line treatment after conventional DMARD
failure compared with a base-case strategy of adalimumab plus
MTX as a ﬁrst-line treatment in ACPA-positive patients with
varying ACPA concentration levels. For patients with poor prog-
nosis (Q3 and Q4), the analysis resulted in increased costs for
abatacept but additional beneﬁts (QALYs).
The costs incurred by abatacept treatment compared with
adalimumab treatment for patients categorized by ACPA groups
are presented in Table 7. With the exception of Q1, treatment
with abatacept resulted in higher treatment costs, because of the
higher response rates for abatacept and hence higher proportion
of patients on long-term therapy, but generally lower hospital-
ization costs because of various factors, including greater HAQ-DI
score reductions after initiating therapy, and delayed disease
progression. Treatment and administration/monitoring costs
were broadly equivalent for patients who received abatacept
and adalimumab across all quartiles.
The QALYs gained with abatacept versus adalimumab tended
to increase with increase in ACPA titer groups, ranging from
0.115 QALYs for Q1 to 0.279 QALYs for Q4 (Table 8). The
difference between treatments in life-years gained was small
and also tended to increase with ACPA titer groups.
In terms of cost effectiveness for Q3 and Q4, the ICER for
abatacept (vs. adalimumab) reduced as the baseline ACPA level
increased with an ICER of £26,272/QALY in Q3 to £6200/QALY in
Q4 (Table 8). In the ﬁrst ACPA group (Q1), abatacept had a lower
QALY gain and a lower cost, resulting in an ICER of £18,397/QALY
in the southwest quadrant. In the southwest quadrant, the
incremental cost reduction should be much larger to accept an
intervention with lower beneﬁts; thus, to be considered cost-
effective, the ratios should be higher. In the second ACPA group
(Q2), abatacept was dominated because it cost slightly more
than adalimumab (þ£66) and resulted in a slight decrease in
QALYs (0.009).
Sensitivity Analyses
The consequences of modifying model parameters applied in
the sensitivity and scenario analysis for Q4 are presented in
Table 9, which presents the range of the ICER between the
Table 7 – Lifetime per-patient costs of treatment with abatacept vs. adalimumab for patients categorized by
ACPA quartile.
Quartile Treatment
cost (£)
Administration and
monitoring costs (£)
Hospitalization
costs (£)
Total lifetime
cost (£)
ABT ADA ABT ADA ABT ADA ABT ADA
Q1 50,188 47,680 9519 9488 16,511 16,189 73,710 75,825
Q2 49,212 49,172 9452 9451 18,949 18,923 77,612 77,546
Q3 47,314 45,976 9178 9211 17,949 18,076 74,441 73,263
Q4 50,685 48,491 8939 8971 18,803 19,234 78,428 76,696
ABT, abatacept; ACPA, anticitrullinated protein antibodies; ADA, adalimumab.
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 1 9 3 – 2 0 2198different assumptions tested in the analysis. For time horizon,
the ICER ranged from £5046/QALY for 5 years to £5954/QALY for
10 years. Changes in the HAQ-DI score reduction on abatacept
treatment had the highest impact on the ICER result; even with
a 20% decrease in the HAQ-DI score reduction on abatacept, the
abatacept treatment strategy remained cost effective at £21,159
per QALY, which was less than the accepted National Health
Service threshold for the cost effectiveness of new therapies
[34]. Incorporating the loading dose cost for the ﬁrst year of
abatacept treatment and extending the abatacept time on treat-
ment to 6.17 years to reﬂect a more severe population [23]
increased the ICER but the abatacept treatment strategy
remained cost effective.
The model was stable when different HAQ-DI score to
utility mapping algorithms were applied, in terms of the ICER.
Nevertheless, using the HAQ-DI score utility algorithm, which
estimated all utilities greater than 0 (0.89 – [0.28  HAQ-DI]), had
a major impact on total QALYs calculated compared with the
base case (6.298 vs. 4.343 for abatacept and 6.057 vs. 4.064 for
adalimumab), although the incremental difference between
abatacept and adalimumab was similar when using the differ-
ent algorithms (0.241 vs. 0.279, respectively). The analysis
indicated that the cost-effectiveness results remained robust
in the face of plausible variations of the main assumptions used
in the model.
Probabilistic Sensitivity Analysis
In the PSA of abatacept versus adalimumab for Q4 patients, 98.5%
of all 1000 simulation results fell in the northeast quadrant of the
cost-effectiveness plane, indicating that the abatacept strategy
was more effective but also more costly in all simulated runs for
the model (Fig. 3). On the basis of the PSA, the probability of eachTable 8 – Cost effectiveness of abatacept vs. adalimumab
Quartile Difference* in
total cost (£)
Life-years (undiscounted)
ABT ADA Differenc
Q1 2115 28.12 28.14 0.02
Q2 66 28.32 28.32 0.01
Q3 1178 26.62 26.61 0.00
Q4 1732 25.92 25.84 0.08
ABT, abatacept; ACPA, anticitrullinated protein antibodies; ADA, adali
adjusted life-year.
* Difference refers to abatacept  adalimumab.
† Lower costs and lower beneﬁts.treatment strategy being cost effective at different decision-
making thresholds (i.e., willingness to pay per QALY gained) is
presented in Fig. 4. There was a 94.2% likelihood that the
abatacept strategy was cost effective at a willingness-to-pay
threshold of £30,000 per QALY gained.Discussion
This is the ﬁrst published economic evaluation to estimate the
cost effectiveness of RA treatments stratiﬁed by subgroups of
patients with RA on the basis of prognostic factor deﬁned by
baseline ACPA levels. This model projected abatacept to be a
cost-effective alternative to adalimumab in Q3 and Q4 of ACPA-
positive patients with RA, showing trends toward increasing
incremental total cost and QALY gain with abatacept versus
adalimumab with increasing ACPA level. The ICER for abatacept
compared with that for adalimumab was the lowest for patients
with the poorest prognosis (ACPA Q4 ICER ¼ £6200/QALY). An
intervention with an ICER lower than £20,000/QALY to £30,000/
QALY gained is generally considered to be cost effective in the UK
health care setting [34]. In the group with the lowest ACPA level,
the ICERs were in the southwest quadrant, that is, lower cost and
lower QALY gains, and therefore the ICERs should be interpreted
with caution.
Previous studies have identiﬁed serum parameters such as RF
and ACPA to be associated with destructive RA [35–38]. Although
the predictive value of RF for joint erosion is mixed, the data on
ACPA are more uniform, with several studies linking ACPA to
erosive disease, comprising structural damage (joint erosions)
and radiographic progression [4,7,8,13]. A systematic review by
Jilani and Mackworth-Young [13] concluded the presence of ACPA
to be a strong predictor of erosive disease. Because establishedfor patients categorized by ACPA quartile.
QALYs ICER (£/QALY)
e* ABT ADA Difference*
5.546 5.661 0.115 18,397†
4.700 4.709 0.009 Dominated
4.697 4.652 0.045 26,272
4.343 4.064 0.279 6200
mumab; ICER, incremental cost-effectiveness ratio; QALY, quality-
Table 9 – Sensitivity analysis of the effect of alternative assumptions (applied to quartile 4).
Analyses Base case Sensitivity analysis Cost per QALY (£)
Base case 6200
Time horizon 40 y 10 y 5954
5 y 5046
ABT HAQ-DI score reduction 0.950 1.14 (þ20%) 4365
0.76 (20%) 21,456
ADA HAQ-DI score reduction 0.750 0.9 (þ20%) 9337
0.6 (20%) 4253
ABT response rate (good) 62.22% 49.78% (20%) Dominant
ABT annual cost £9275 £15,756 (full UK list price) 81,345
£12,257 39,775
ABT loading dose cost included in
ﬁrst year
£0 £907.20 8770
ABT time on treatment 4.06 y 6.17 y 12,539
Utility equation 0.804  0.203  HAQ-DI  0.045  HAQ-DI2 EQ-5D ¼ 0.89  (0.28  HAQ-DI) 6447
EQ-5D ¼ 0.76  (0.28  HAQ-DI) 6299
ABT, abatacept; ADA, adalimumab; EQ-5D, EuroQol ﬁve-dimensional questionnaire; HAQ-DI, Health Assessment Questionnaire Disability
Index; QALY, quality-adjusted life-year.
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 1 9 3 – 2 0 2 199RA is a heterogeneous disease, some patients experience aggres-
sive disease in spite of treatment. These patients also have
higher use of direct medical resource as well as overall and RA-
speciﬁc costs [39–41]. Thus, targeting these patients with biologic
DMARDs is important.
Reliable markers of prognoses of aggressive RA, such as ACPA,
can provide at baseline the rationale for aggressive therapy in
patients with a substantial risk of developing destructive disease.
In addition to evaluating the clinical beneﬁt of aggressive treat-
ments in patients at risk, one would need to consider the cost-
effectiveness of pursuing such a policy. Our analysis was geared
toward evaluating the appropriate cost-effective alternative bio-
logic DMARD intervention in managing patients with poor prog-
nosis and thus at risk of disease progression. Similar to our
ﬁndings, another analysis has also shown biologic DMARDs to be
cost effective in patients at risk of rapid disease progression [42].
Our analysis, however, takes this work a step further byFig. 3 – Cost-effectiveness plot of probabilistic sensitivity
analysis results (abatacept vs. adalimumab). QALY, quality-
adjusted life-year.specifying the prognostic factors and comparing one biologic
DMARD with another, demonstrating that abatacept provided a
cost-effective alternative to adalimumab in patients with poor
prognosis who had an inadequate response to MTX.
The AMPLE study was chosen as a source of model inputs by
way of it being the only head-to-head, randomized, controlled
study between two biologics that incorporates radiographic pro-
gression end points, provides data on erosions and joint space
narrowing in patients with RA, and includes data presented by
patient ACPA level [15,16]. The demographic and clinical charac-
teristics of the patients at AMPLE study baseline were balanced
across the treatment groups and were considered to be typical for
RA studies (the mean age of the patients was 51 years and the
mean DAS28-CRP score was 5.5  1.1 in both groups, with equal
proportions of patients with moderate and high disease activity
in each group [15]). Abatacept and adalimumab provided sim-
ilarly effective treatment outcomes in patients with RA [15,16]. AsFig. 4 – Cost-effectiveness acceptability curve (abatacept vs.
adalimumab). MTX, methotrexate.
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 1 9 3 – 2 0 2200in the AMPLE study, the model compared abatacept with adali-
mumab; the lack of ACPA quartile data for other treatments
currently prohibits running such comparisons for other treat-
ment combinations. Apart from the AMPLE study, data based on
real-world RA registries have demonstrated an association
between higher ACPA concentrations and improved abatacept
efﬁcacy and retention [14,42–45]. Therefore, we believe that the
AMPLE study provided the model with reliable comparative
efﬁcacy data for a population representative of the general RA
population and for two agents where patient ACPA level could be
expected to inﬂuence outcomes and costs.
A key strength of this model is the application of the approach
considered by evidence review groups responsible for assessing
the cost effectiveness of RA treatments in the United Kingdom
[1,23]. Decision making on the use of treatments for RA in the
United Kingdom is based on IPS models, such as the Birmingham
rheumatoid arthritis model [20] and the Shefﬁeld rheumatoid
arthritis health economic model [21]. As with other IPS models,
this cost-effective analysis enabled patient progression while on
a certain treatment if a speciﬁc disease level was met, allowed
treatment sequences to be evaluated rather than single therapy,
and incorporated the uncertain duration of treatment effect on
each patient [21].
As with any economic evaluation study, it is important to
acknowledge the limitations of the analysis and to reﬂect on the
assumptions and data upon which the conclusions have
been drawn.
In terms of the patient population characteristics taken from
the AMPLE study, although the study population was reasonably
large (646 participants), the number of patients in each trial arm
by ACPA quartile was relatively small (42–55 participants), which
may reduce conﬁdence in the effectiveness estimates by ACPA
quartile that were used as inputs.
The present analysis explored the relationship between
ACPA level and ICER using ACPA level quartiles and did not
attempt to identify any ACPA threshold corresponding to a
single ICER value or model outcomes according to ACPA levels
of clinical signiﬁcance. As such, the association is deserving of
further study. Such an analysis might require an alternative
outcome, such as response rate. Thresholds at which the best
response rate occurs could then be investigated using, for
example, a receiver-operating characteristic curve to determine
the best combination of sensitivity and speciﬁcity. This is not
possible using the model in its current form because the model
uses response rate as an input parameter rather than as an
outcome. A future economic analysis might also consider the
cost effectiveness of a treatment algorithm incorporating
screening for ACPA level and subsequent treatment of a pre-
determined patient subset versus no screening and the treat-
ment of all patients. The present study evaluated the impact of
prognostic factor such as ACPA levels on cost effectiveness and
not the impact of a screening strategy.
In addition, the base case assumed that HAQ-DI score pro-
gression while on biologic therapy was 0. This assumption is used
in most cost-effectiveness models and the literature is mixed
because some analyses show that patients with RA treated with a
TNF inhibitor have continued disease activity [23]. For patients
on palliative care, a constant annual rate of HAQ-DI score
progression was assumed. A recent NICE appraisal (Technology
Appraisal 375 [28]) has suggested a nonlinear HAQ-DI score
progression model, derived from an early RA data registry, for
patients on conventional DMARDs and palliative care is a more
appropriate reﬂection of a chronic disease, and that the choice of
model to inform HAQ-DI score progression had an impact on
ICERs. It is not clear how the use of a cubic representation ofHAQ-DI score progression would affect the results of the current
model, but it is expected that because the treatment strategy
after failure of ﬁrst-line treatment is the same for both treatment
arms, the incremental results would not change greatly.
The utility measures of the EQ-5D were based on a mapping
of the HAQ-DI score to utility described by Malottki et al. [23]
and used in multiple cost-effectiveness models. Such mapping
studies usually overestimate the utilities of bad health states
and underestimate the utilities of good health states. It has
been suggested that a substantially better estimate of utility
is obtained by the inclusion of pain alongside the HAQ-DI
than via the HAQ-DI alone [28]. The application of different
utility mapping algorithms in this study was investigated
in sensitivity analyses and had little impact on the incre-
mental results, but the use of a mapping algorithm incorporating
pain as well as the HAQ-DI score should be investigated in
future work.
Finally, because of availability of data, the model evaluated
abatacept against one anti-TNF agent only (adalimumab) and
incorporated clinical data for these two agents only from the
observational trial. The model also did not assess the introduc-
tion of a second conventional DMARD after MTX failure because
the model and the AMPLE trial were reﬂecting treatment guide-
lines for the patients with poor prognosis. The limited use of
comparators in this study creates an opportunity for further
research to assess the cost effectiveness of abatacept versus
other conventional and biologic treatment options.
For the next treatment in the sequence (etanercept), it was
assumed that the relative difference in EULAR response proba-
bilities observed for adalimumab between the AMPLE study and a
recent previous mixed treatment comparison [28] would be
similar for etanercept. It is, however, unlikely that this would
have favored either abatacept or adalimumab, because patients
in each treatment arm moved on to etanercept after failure on
the ﬁrst line of therapy. We tested the impact of these assump-
tions on the ﬁndings via various sensitivity and scenario analy-
ses. Overall, we found that the results were robust in the face of
changes in input parameters, yet the opportunity remains
to evaluate abatacept against other agents and to increase
the clinical data inputs contributing to the robustness of
the model.Conclusions
Abatacept provided a cost-effective alternative to adalimumab in
ACPA-positive patients with RA with an inadequate response to
MTX. For ACPA-positive patients with higher ACPA levels (Q4 and
Q3), higher EULAR response rates for abatacept patients com-
pared with adalimumab patients resulted in higher proportions
of patients on long-term therapy resulting in increased treatment
costs, but these were partially offset by a greater reduction in
disability (HAQ-DI) and lower hospitalization costs. The increased
cost per QALY gained for abatacept was lower in those patients
with higher ACPA levels. This economic evaluation, therefore,
suggests that the use of abatacept in patients with RA with poor
prognosis should be seen as a cost-effective approach to the
management of RA in the United Kingdom, with clear advantages
seen in health-related quality of life.
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